Dialysate sodium gradient and interdialytic weight gain
A 52-year-old man receives thrice-weekly 3.5-hour hemodialysis with dialysate sodium 140 mEq/L. He urinates about 100 mL/day and inconsistently follows sodium and fluid restriction. Dry weight is 70 kg, predialysis weight averages 76 kg, and predialysis BP averages 170/95 mm Hg. He has no intradialytic hypotension. He cannot extend treatment time or attend extra sessions, and unit policy caps ultrafiltration at 13 mL/kg/h (goal 3.1 L per treatment). He has elevated jugular venous pressure, bibasilar crackles, and moderate pretibial edema. Predialysis sodium is 135 mEq/L. Which intervention is most likely to decrease his interdialytic weight gain?
- A.Decrease dialysate sodium concentrationCorrect
- B.Advise fluid and sodium restriction
- C.Prescribe sodium modeling
- D.Prescribe metolazone
Explanation
The intervention most likely to decrease his interdialytic weight gain is to lower the dialysate sodium concentration. His predialysis serum sodium is 135 mEq/L, but he dialyzes against a sodium of 140 mEq/L. That 5 mEq/L gradient drives diffusive sodium transfer into the patient during every treatment, raising postdialysis serum sodium and tonicity. The rise triggers thirst, and the patient drinks until his sodium returns to his individual set point, which produces weight gain between sessions. Because he cannot extend treatment time or add sessions, and the unit caps ultrafiltration at 13 mL/kg/h, he cannot reach dry weight, leaving him hypertensive with edema, elevated jugular venous pressure, and crackles. Setting dialysate sodium close to his predialysis level (for example, 135 to 137 mEq/L) removes the diffusive sodium load. Systematic reviews of lower dialysate sodium show reductions in interdialytic weight gain and BP. Intradialytic hypotension is the main risk, but he has none. The intervention needs no added effort from the patient, which matters given his inconsistent adherence. Advising fluid and sodium restriction remains important, but he has received this advice and adheres inconsistently. Counseling alone is less likely to change weight gain than eliminating the sodium load delivered by the dialysate itself, and the thirst induced by sodium loading makes fluid restriction harder to follow. Metolazone requires functioning nephrons to produce natriuresis. With urine output of about 100 mL/day, a thiazide-type diuretic will not meaningfully increase sodium excretion and adds risks of hyponatremia and hypokalemia. Sodium modeling, in which dialysate sodium is set high early in treatment and lowered later, was designed to reduce intradialytic hypotension and cramps. It usually results in a net positive sodium balance, increasing thirst, weight gain, and BP, the opposite of the desired effect.
Why each option
- A.
- Correct. Dialysate sodium 140 mEq/L against serum 135 mEq/L loads sodium each session, driving thirst; lowering it toward serum sodium reduces interdialytic weight gain.
- B.
- He already receives restriction advice and adheres inconsistently; dialysate sodium loading increases thirst, so counseling alone is unlikely to reduce weight gain.
- C.
- Sodium modeling raises early dialysate sodium to prevent hypotension and usually causes net sodium gain, worsening thirst, weight gain, and hypertension.
- D.
- With urine output near 100 mL/day, few functioning nephrons remain, so metolazone cannot produce meaningful natriuresis and only adds hyponatremia and hypokalemia risk.
Reference: Dunlop JL, Cochrane Database Syst Rev 2019 (low dialysate sodium in maintenance hemodialysis); Munoz Mendoza J, Nephrol Dial Transplant 2011 (dialysate sodium and the sodium gradient in maintenance hemodialysis)
This is one of 1,100 questions in the MedBoardSA nephrology bank, with timed test mode, tutor mode, and progress tracking by topic.
Practise the full bankMore Hemodialysis questions
- Dialysate sodium and interdialytic weight gain
- ESA dose titration after inadequate initial response
- Impending rupture of an arteriovenous fistula aneurysm
- Latent TB screening with IGRA in BCG-vaccinated dialysis patients
- Lipid-lowering therapy not initiated in maintenance dialysis
- Protein-energy wasting in maintenance hemodialysis
Browse other topics
- Electrolyte Disorders (15)
- CKD Management (12)
- AKI (11)
- Transplant (10)
- Primary GN (9)
- HTN (8)
- Secondary GN (7)
- Genetic GN (3)
- Diabetic Nephropathy (3)
- Peritoneal Dialysis (3)
- Nephrolithiasis (3)
- CKD Bone Disease (2)
- Calcium Metabolism (2)
- Dysproteinemias (1)
- Secondary HPT (1)
- Drug-Induced GN (1)
- Phosphate & FGF23 (1)
- Calciphylaxis (1)